Inhibition of transforming growth factor-β release from tumor cells reduces their motility associated with epithelial-mesenchymal transition

Ohshio,Yasuhiko; Teramoto,Koji; Hashimoto,Masayuki; Kitamura,Shoji; Hanaoka,Jun; Kontani,Keiichi

doi:10.3892/or.2013.2505

Inhibition of transforming growth factor-β release from tumor cells reduces their motility associated with epithelial-mesenchymal transition

Authors:
- Yasuhiko Ohshio
- Koji Teramoto
- Masayuki Hashimoto
- Shoji Kitamura
- Jun Hanaoka
- Keiichi Kontani
View Affiliations

Affiliations: Department of Surgery, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan, Department of Respiratory, Breast and Endocrine Surgery, Kagawa University Faculty of Medicine, Kita-gun, Kagawa 561-0793, Japan
Published online on: May 28, 2013 https://doi.org/10.3892/or.2013.2505
Pages: 1000-1006

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The high level of transforming growth factor‑β (TGF‑β) in tumor tissue, which is primarily released from tumor cells, helps maintain their metastatic nature and exacerbates the creation of a pro-tumor microenvironment. Although the strategy of targeting TGF‑β in cancer therapy has shown promise, its effects remain limited. In the present study, we focused on tumor cells as sources of TGF‑β release, and hypothesized that inhibition of their TGF‑β release could suppress their epithelial-mesenchymal transition (EMT)-associated metastatic nature and inactivate the induction of suppressor immune cells. To investigate this hypothesis, LLC1 cells, a mouse lung cancer cell line, were cultured with the TGF‑β release inhibitor tranilast and the motility of LLC1 cells was examined. Furthermore, to examine whether inhibition of TGF‑β release influences the induction of regulatory T (Treg) cells, spleen cells from normal mice were cultured in medium in which LLC1 cells had been cultured with tranilast. The results showed that tranilast inhibited the release of TGF‑β1 from LLC1 cells without affecting their proliferation. Inhibition of TGF‑β1 release suppressed the invasive activity of LLC1 cells, but enhanced their activity to adhere. mRNA levels of Slug and Twist were decreased in LLC1 cells, whereas levels of E‑cadherin were recovered. Treg cells were less frequently induced by medium in which LLC1 cells had been cultured with tranilast. Taken together, inhibition of TGF‑β1 release dampens the metastatic nature of LLC1 cells through the downregulation of EMT and possesses the possibility to improve antitumor immune responses through suppression of Treg cell induction. These findings provide a new rationale for development of TGF‑β‑targeted molecular immunotherapy against cancer.

View Figures

View References

1	Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, Du Z, Desprez PY, Anver MR, Michalowska AM, Shih J, Parks WT and Wakefield LM: Transforming growth factor-β can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res. 67:8643–8652. 2007.
2	Forrester E, Chytil A, Bierie B, Aakre M, Gorska AE, Sharif-Afshar AR, Muller WJ and Moses HL: Effect of conditional knockout of the type II TGF-β receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res. 65:2296–2302. 2005.
3	Jakowlew SB: Transforming growth factor-β in cancer and metastasis. Cancer Metastasis Rev. 25:435–457. 2006.
4	Galliher AJ, Neil JR and Schiemann WP: Role of transforming growth factor-β in cancer progression. Future Oncol. 2:743–763. 2006.
5	Talbot LJ, Bhattacharya SD and Kuo PC: Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol. 3:117–136. 2012.PubMed/NCBI
6	Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
7	Letterio JJ and Roberts AB: Regulation of immune responses by TGF-β. Annu Rev Immunol. 16:137–161. 1998.
8	Wrzesinski SH, Wan YY and Flavell RA: Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res. 13:5262–5270. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G and Wakefield LM: Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest. 109:1607–1615. 2002.PubMed/NCBI
10	Frazier K, Thomas R, Scicchitano M, Mirabile R, Boyce R, Zimmerman D, Grygielko E, Nold J, DeGouville AC, Huet S, Laping N and Gellibert F: Inhibition of ALK5 signaling induces physeal dysplasia in rats. Toxicol Pathol. 35:284–295. 2007. View Article : Google Scholar : PubMed/NCBI
11	Prud'homme GJ: Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest. 87:1077–1091. 2007.
12	Fujita T, Teramoto K, Ozaki Y, Hanaoka J, Tezuka N, Itoh Y, Asai T, Fujino S, Kontani K and Ogasawara K: Inhibition of transforming growth factor-β-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res. 69:5142–5150. 2009.
13	Suzawa H, Kikuchi S, Ichikawa K and Koda A: Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE₂ from human monocytes-macrophages. Jpn J Pharmacol. 60:85–90. 1992. View Article : Google Scholar : PubMed/NCBI
14	Kudo-Saito C, Shirako H, Takeuchi T and Kawakami Y: Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
15	Tanaka K, Honda M, Kuramochi T and Morioka S: Prominent inhibitory effects of tranilast on migration and proliferation and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 107:179–185. 1994. View Article : Google Scholar : PubMed/NCBI
16	Hiroi M, Onda M, Uchida E and Aimoto T: Anti-tumor effect of N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) on experimental pancreatic cancer. J Nippon Med Sch. 69:224–234. 2002.
17	Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET and Namiki M: Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β1-associated osteoblastic changes. Prostate. 69:1222–1234. 2009.PubMed/NCBI
18	Subramaniam V, Chakrabarti R, Prud'homme GJ and Jothy S: Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anticancer Drugs. 21:351–361. 2010. View Article : Google Scholar : PubMed/NCBI
19	Shime H, Kariya M, Orii A, Momma C, Kanamori T, Fukuhara K, Kusakari T, Tsuruta Y, Takakura K, Nikaido T and Fujii S: Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21^waf1 and p53. J Clin Endocrinol Metab. 87:5610–5617. 2002. View Article : Google Scholar : PubMed/NCBI
20	Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J and Weller M: N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-β relesase and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer. 93:53–61. 2001.
21	Chakrabarti R, Subramaniam V, Abdalla S, Jothy S and Prud'homme GJ: Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs. 20:334–345. 2009. View Article : Google Scholar : PubMed/NCBI
22	Kato K, Tamai H, Hayakawa H, Yamaguchi T, Kanmatsuse K, Haze K, Aizawa T, Suzuki S, Takase S, Suzuki T, Nishikawa H, Nakanishi S, Kato O and Nakashima M: Clinical evaluation of tranilast on restenosis after percutaneous transluminal coronary angioplasty (PTCA) - a double blind placebo-controlled comparative study. J Clin Therapy Med. 12:65–85. 1996.
23	Zhou Y, Poczatek MH, Berecek KH and Murphy-Ullrich JE: Thrombospondin 1 mediates angiotensin II induction of TGF-β activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun. 339:633–641. 2006.PubMed/NCBI
24	Miyajima A, Asano T and Hayakawa M: Captopril restores transforming growth factor-β type II receptor and sensitivity to transforming growth factor-β in murine renal cell cancer cells. J Urol. 165:616–620. 2001.PubMed/NCBI
25	Yilmaz M and Christofori G: Mechanisms of motility in metastasizing cells. Mol Cancer Res. 8:629–642. 2010. View Article : Google Scholar : PubMed/NCBI
26	Margadant C and Sonnenberg A: Integrin-TGF-β crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11:97–105. 2010.
27	Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA and Lee C: Tumor evasion of the immune system by converting CD4⁺CD25⁻ T cells into CD4⁺CD25⁺ T regulatory cells: role of tumor-derived TGF-β. J Immunol. 178:2883–2892. 2007. View Article : Google Scholar : PubMed/NCBI
28	Conroy H, Galvin KC, Higgins SC and Mills KH: Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells. Cancer Immunol Immunother. 61:425–431. 2012.